AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32237143 — intervention group
Group type: EXPERIMENTAL
Intervention: Group game intervention including routine preoperative preparation and group game
Number of subjects: 94
Study 32237143 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 94
Study 35313733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation-based rhythm control
Number of subjects: 411
Study 35313733 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 411
Study 33466137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nursing care
Number of subjects: 0
Study 33466137 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34056698 — intervention group
Group type: COMPARATOR
Intervention: Negative control (0 ppm F; no TMP)
Number of subjects: 60
Study 34056698 — intervention group
Group type: EXPERIMENTAL
Intervention: F500 (500 ppm NaF)
Number of subjects: 60
Study 34056698 — intervention group
Group type: EXPERIMENTAL
Intervention: F1500 (1500 ppm NaF-positive control)
Number of subjects: 60
Study 34056698 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP (1% TMP)
Number of subjects: 60
Study 34056698 — intervention group
Group type: EXPERIMENTAL
Intervention: F + TMP (500 ppm NaF + 1% TMP)
Number of subjects: 60
Study 33315081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting intervention
Number of subjects: 0
Study 36436532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy with aerobic exercise (10 min aerobic exercise after nine 90‐min weekly sessions of exposure therapy)
Number of subjects: 130
Study 36436532 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy with passive stretching (10 min passive stretching after nine 90‐min weekly sessions of exposure therapy)
Number of subjects: 130
Study 35353186 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyoto Prognostic Index (KPI)
Number of subjects: 58
Study 35353186 — intervention group
Group type: COMPARATOR
Intervention: International Prognostic Index (IPI)
Number of subjects: 58
Study 33043351 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic micro-veneer
Number of subjects: 120
Study 33043351 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive ultra-thin veneer
Number of subjects: 120
Study 32388690 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMB video condition
Number of subjects: 153
Study 32388690 — intervention group
Group type: COMPARATOR
Intervention: Comparison video condition
Number of subjects: 153
Study 32388690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study 32184123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 3 g intravenous infusion
Number of subjects: 14
Study 32184123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, 0.9% NaCl) intravenous infusion
Number of subjects: 14
Study 35315512 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hypofractionated radiation of 52.5 Gy in 15 fractions
Number of subjects: 62
Study 33685854 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape COVID‐19 serious game
Number of subjects: 295
Study 33685854 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard IPC material)
Number of subjects: 295
Study 35331007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BG control (target BG 80-130 mg/dL) for 72 hours
Number of subjects: 1151
Study 35331007 — intervention group
Group type: COMPARATOR
Intervention: Standard BG control (target BG 80-179 mg/dL) for 72 hours
Number of subjects: 1151
Study 33142785 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with liver cancer
Number of subjects: 80574
Study 33142785 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with lung cancer
Number of subjects: 80574
Study 33142785 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with cancer (overall)
Number of subjects: 80574
Study 33142785 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer patients (control group)
Number of subjects: 80574
Study 36071520 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate–mefloquine (AS/MQ)
Number of subjects: 211
Study 36071520 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin–piperaquine (DHA/PPQ)
Number of subjects: 211
Study 36071520 — intervention group
Group type: EXPERIMENTAL
Intervention: atovaquone–proguanil (ATQ/PG)
Number of subjects: 211
Study 34198463 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system based on radiomics and clinical indices
Number of subjects: 107
Study 34255417 — intervention group
Group type: EXPERIMENTAL
Intervention: ESCP Safe Anastomosis Intervention
Number of subjects: 4440
Study 34255417 — intervention group
Group type: COMPARATOR
Intervention: Control (standard practice)
Number of subjects: 4440
Study 32079968 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted obesity prevention intervention program (Healthy Balance) for Latinx immigrant families.
Number of subjects: 92
Study 32079968 — intervention group
Group type: COMPARATOR
Intervention: Original and translated group intervention for a heterogeneous population.
Number of subjects: 92
Study 35939332 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided PVI
Number of subjects: 225
Study 35939332 — intervention group
Group type: COMPARATOR
Intervention: CF-guided PVI
Number of subjects: 225
Study 34273114 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil amended with organic P (Class B biosolids applied at 45 Mg ha‐1)
Number of subjects: 20
Study 34273114 — intervention group
Group type: COMPARATOR
Intervention: Miscanthus planted in untilled soil, no amendments
Number of subjects: 20
Study 34273114 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil
Number of subjects: 20
Study 34273114 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscanthus planted in tilled soil amended with inorganic P (triple superphosphate applied at 5:3 Pb:P)
Number of subjects: 20
Study 34273114 — intervention group
Group type: COMPARATOR
Intervention: Existing vegetation
Number of subjects: 20
Study 32948644 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative AKI (Kidney Disease Improving Global Outcomes definition)
Number of subjects: 124
Study 32948644 — intervention group
Group type: COMPARATOR
Intervention: Non-AKI participants
Number of subjects: 124
Study 32948644 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged <2 years at surgery
Number of subjects: 124
Study 34782191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive oral dexamethasone
Number of subjects: 401
Study 34782191 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 401
Study 33060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine hydration (1 ml/kg/h, 0.9% sodium chloride) for 3-12 hours before and 24 hours after contrast exposure
Number of subjects: 401
Study 33060531 — intervention group
Group type: COMPARATOR
Intervention: Nonhydration (control group)
Number of subjects: 401
Study 32187256 — intervention group
Group type: EXPERIMENTAL
Intervention: 200.000 IU of cholecalciferol (vitamin D)
Number of subjects: 11
Study 32187256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 35110644 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoRehab program (parent-provided interventions including vocal soothing, scent exchange, comforting touch, skin-to-skin care, massage, and physical therapy)
Number of subjects: 70
Study 35110644 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 35110644 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoRehab program
Number of subjects: 70
Study 33892393 — intervention group
Group type: EXPERIMENTAL
Intervention: loadsol®
Number of subjects: 43
Study 33829415 — intervention group
Group type: EXPERIMENTAL
Intervention: RadscoreFDG_T1WI_SWI model (optimal model comprising structural (T1WI), functional (SWI) and metabolic (18F-FDG) sequences)
Number of subjects: 90
Study 33829415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiomics integrated model (incorporating RadscoreFDG_T1WI_SWI, three clinical symptoms, and SUVmax)
Number of subjects: 90
Study 33829415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-radiomics integrated model
Number of subjects: 90
Study 34363130 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart wearable devices
Number of subjects: 0
Study 34363130 — intervention group
Group type: COMPARATOR
Intervention: Mobile app (Control)
Number of subjects: 0
Study 32979235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0
Study 32979235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0
Study 32979235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32270636 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiaotong qiaomai needling technique of acupuncture
Number of subjects: 64
Study 32270636 — intervention group
Group type: COMPARATOR
Intervention: Routine needling technique of acupuncture and rehabilitation exercise (Control)
Number of subjects: 64
Study 35348584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 144
Study 34207794 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 417
Study 35684956 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cultural care training program
Number of subjects: 80
Study 35684956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 36396531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tungsten carbide bur (TCB)
Number of subjects: 40
Study 36396531 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler (US)
Number of subjects: 40
Study 35202591 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 941
Study 35202591 — intervention group
Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 941
Study 32046647 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care using the Keele STarT MSK Tool
Number of subjects: 524
Study 32046647 — intervention group
Group type: COMPARATOR
Intervention: Non-stratified care
Number of subjects: 524
Study 35980648 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised management combined with drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Number of subjects: 60
Study 35980648 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment (silver ion alginate, hydrocolloid and foam dressings)
Number of subjects: 60
Study 35980648 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised management combined with drug treatment
Number of subjects: 60
Study 33307383 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal‐Design‐symbol
Number of subjects: 346
Study 33307383 — intervention group
Group type: COMPARATOR
Intervention: ISA
Number of subjects: 346
Study 33307383 — intervention group
Group type: COMPARATOR
Intervention: Motion‐symbol
Number of subjects: 346
Study 33307383 — intervention group
Group type: COMPARATOR
Intervention: All-symbols
Number of subjects: 346
Study 32621144 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA as a diagnostic tool
Number of subjects: 0
Study 32621144 — intervention group
Group type: COMPARATOR
Intervention: Routine interventional strategy in addition to optimal medical therapy
Number of subjects: 0
Study 33930204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 80
Study 33930204 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 80
Study 33338035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis on the unequal aspect of the pandemic (focusing on the elderly and those with medical conditions)
Number of subjects: 0
Study 33338035 — intervention group
Group type: EXPERIMENTAL
Intervention: Language that emphasizes the impact of the virus on all of us
Number of subjects: 0
Study 35843106 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of fructooligosaccharide (FOS)
Number of subjects: 0
Study 35843106 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of partially hydrolyzed guar gum (PHGG)
Number of subjects: 0
Study 35843106 — intervention group
Group type: COMPARATOR
Intervention: 20 g of digestible maltodextrin (placebo)
Number of subjects: 0
Study 33470727 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily financial incentives linked to real-time adherence monitoring
Number of subjects: 29
Study 33470727 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 29
Study 32333898 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab 120 mg
Number of subjects: 168
Study 32333898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 35984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Led Symptom Management Program (NL-SMP)
Number of subjects: 41
Study 35984917 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 41
Study 33464762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (1st line treatment)
Number of subjects: 0
Study 33464762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (2nd line treatment)
Number of subjects: 0
Study 33464762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32855201 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 146
Study 32855201 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery (diagnostic knee arthroscopy)
Number of subjects: 146
Study 34896645 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinic care
Number of subjects: 188
Study 34896645 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 188
Study 32746841 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based intervention supported with problem-solving therapy
Number of subjects: 67
Study 32746841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 35449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (initial dose 7.5 mg)
Number of subjects: 0
Study 35449020 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (initial limit 1000 ml per 24 h)
Number of subjects: 0
Study 35449020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 35449020 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction
Number of subjects: 0
Study 33815069 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive peripheral nerve magnetic stimulation (rPNMS) at 20 Hz on the median nerve of the non-dominant hand.
Number of subjects: 46
Study 33815069 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no stimulation output).
Number of subjects: 46
Study 32299478 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim Improvement Package (VIP)
Number of subjects: 226
Study 32299478 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 226
Study 35390509 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 884
Study 35390509 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 884
Study 32921252 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive extracorporeal circulation
Number of subjects: 60
Study 32921252 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 60
Study 32314298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal agent + CO2 laser ablation once a month for the first 3 months
Number of subjects: 160
Study 32314298 — intervention group
Group type: COMPARATOR
Intervention: Topical antifungal agent
Number of subjects: 160
Study 32314298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal agent + CO2 laser ablation
Number of subjects: 160
Study 34004077 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 45
Study 32965224 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages for drowning prevention
Number of subjects: 800
Study 34465254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Hysterectomy (SILH)
Number of subjects: 50
Study 34465254 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic Hysterectomy (CLH)
Number of subjects: 50
Study 33966560 — intervention group
Group type: EXPERIMENTAL
Intervention: BARKH-based algorithm for identification and treatment of hypertensive emergencies
Number of subjects: 0
Study 32931137 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stoma
Number of subjects: 232
Study 32931137 — intervention group
Group type: COMPARATOR
Intervention: Not having a defunctioning stoma (Control)
Number of subjects: 232
Study 36146869 — intervention group
Group type: EXPERIMENTAL
Intervention: Loopdeetect COVID‐19
Number of subjects: 741
Study 36146869 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR Allplex 2019 n-Cov
Number of subjects: 741
Study 34582281 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment seeking participants
Number of subjects: 281
Study 34582281 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 281
Study 34582281 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment seeking participants
Number of subjects: 281
Study 33038932 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated palliative care approach
Number of subjects: 0
Study 33038932 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 35985097 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital interventions targeting ED psychopathology
Number of subjects: 600
Study 35985097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study 35985097 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline positive body image constructs
Number of subjects: 600
Study 33031782 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE intervention implemented after October 1, 2018
Number of subjects: 447
Study 33031782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellations of orders
Number of subjects: 447
Study 33031782 — intervention group
Group type: EXPERIMENTAL
Intervention: Expired orders
Number of subjects: 447
Study 33031782 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled orders
Number of subjects: 447
Study 33031782 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed orders
Number of subjects: 447
Study 32444309 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOIT (slow low-dose oral immunotherapy)
Number of subjects: 170
Study 32444309 — intervention group
Group type: COMPARATOR
Intervention: Control (complete avoidance)
Number of subjects: 170
Study 32812489 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling session, information booklet about DFV, and contact details of the counselor
Number of subjects: 140
Study 32812489 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus a booklet containing contact details of local DFV support services
Number of subjects: 140
Study 33798303 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin and auricular point sticking therapy
Number of subjects: 90
Study 33798303 — intervention group
Group type: COMPARATOR
Intervention: Estazolam 1 mg, once daily for 12 days
Number of subjects: 90
Study 35511528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 190
Study 35511528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 35262424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 456
Study 35262424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 34658360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with alteplase in addition to routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Number of subjects: 152
Study 34658360 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (antiplatelet aggregation, statins, neuroprotection, and drugs that stimulate blood flow)
Number of subjects: 152
Study 34658360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with alteplase in addition to routine therapy
Number of subjects: 152
Study 34658360 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 152
Study 34283313 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 196
Study 34283313 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery (pN3)
Number of subjects: 196
Study 34283313 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 196
Study 34283313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (CRT)
Number of subjects: 196
Study 34283313 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 196
Study 34271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 14 days
Number of subjects: 120
Study 34271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 0, 3 days
Number of subjects: 120
Study 34271194 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding after starvation for 3 days
Number of subjects: 120
Study 35105559 — intervention group
Group type: EXPERIMENTAL
Intervention: i²TransHealth internet-based health care programme for 4 months
Number of subjects: 163
Study 35105559 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting group)
Number of subjects: 163
Study 34096012 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ticagrelor maintenance dose with or without acetylsalicylic acid (ASA) withdrawal
Number of subjects: 0
Study 34096012 — intervention group
Group type: COMPARATOR
Intervention: Standard dose ticagrelor with dual antiplatelet treatment (DAPT)
Number of subjects: 0
Study 33243764 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic Stress Disorder Checklist (PTSD)
Number of subjects: 1092